Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 16;12(12):3790.
doi: 10.3390/cancers12123790.

Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis

Wieke C H Visser  1 , Hans de Jong  1 , Willem J G Melchers  1   2 , Peter F A Mulders  3 , Jack A Schalken  3
Affiliations
Review

Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis

Wieke C H Visser et al. Cancers (Basel). .

Abstract

In the diagnosis and prognosis of prostate cancer (PCa), the serum prostate-specific antigen test is widely used but is associated with low specificity. Therefore, blood-, urinary- and tissue-based biomarker tests have been developed, intended to be used in the diagnostic and prognostic setting of PCa. This review provides an overview of commercially available biomarker tests developed to be used in several clinical stages of PCa management. In the diagnostic setting, the following tests can help selecting the right patients for initial and/or repeat biopsy: PHI, 4K, MiPS, SelectMDx, ExoDx, Proclarix, ConfirmMDx, PCA3 and PCMT. In the prognostic setting, the Prolaris, OncotypeDx and Decipher test can help in risk-stratification of patients regarding treatment decisions. Following, an overview is provided of the studies available comparing the performance of biomarker tests. However, only a small number of recently published head-to-head comparison studies are available. In contrast, recent research has focused on the use of biomarker tests in relation to the (complementary) use of multiparametric magnetic resonance imaging in PCa diagnosis.

Keywords: cancer biomarkers; liquid biopsies; prostate cancer; sPSA.

PubMed Disclaimer

Conflict of interest statement

W.C.H.V., H.d.J. and W.J.G.M. are employees of MDxHealth. J.A.S. is a consultant for MDxHealth.

Figures

Figure 1
Figure 1
Schematic overview of commercialized prostate cancer biomarker tests intended to be used in various clinical settings.
See this image and copyright information in PMC

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat. Rev. Cancer. 2008;8:268–278. doi: 10.1038/nrc2351. - DOI - PubMed
    1. Loeb S., Sanda M.G., Broyles D.L., Shin S.S., Bangma C.H., Wei J.T., Partin A.W., Klee G.G., Slawin K.M., Marks L.S., et al. The prostate health index selectively identifies clinically significant prostate cancer. J. Urol. 2015;193:1163–1169. doi: 10.1016/j.juro.2014.10.121. - DOI - PMC - PubMed
    1. Catalona W.J., Partin A.W., Sanda M.G., Wei J.T., Klee G.G., Bangma C.H., Slawin K.M., Marks L.S., Loeb S., Broyles D.L., et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/mL prostate specific antigen range. J. Urol. 2011;185:1650–1655. doi: 10.1016/j.juro.2010.12.032. - DOI - PMC - PubMed
    1. Stephan C., Vincendeau S., Houlgatte A., Cammann H., Jung K., Semjonow A. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin. Chem. 2013;59:306–314. doi: 10.1373/clinchem.2012.195784. - DOI - PubMed

LinkOut - more resources